What is it about?

Human African trypanosomiasis is a fatal parasitic disease unless treated. Eflornithine is a recommended treatment in the disease stage when the parasites have infected the central nervous system. Eflornithine is currently dosed intravenously as a 50/50 mixture of L-eflornithine and D-eflornithine. An oral treatment wth eflornithine would be better. We have characterized the anti-parasitic effect of L-eflornithine, D-eflornithine and the L- and D-eflornithine combination in the laboratory and showed that L-eflornithine was a 9-fold more potent drug compared to D-eflornithine.

Featured Image

Why is it important?

Our laboratory findings are important as they can be used in the future to further investigate the potential for an oral eflornithine-based treatment using L-eflornithine against this neglected tropical disease.

Read the Original

This page is a summary of: Enantiospecific antitrypanosomal in vitro activity of eflornithine, PLoS Neglected Tropical Diseases, July 2021, PLOS, DOI: 10.1371/journal.pntd.0009583.
You can read the full text:



The following have contributed to this page